196 related articles for article (PubMed ID: 25186974)
1. Competitive mode and site of interaction of ticagrelor at the human platelet P2Y12 -receptor.
Hoffmann K; Lutz DA; Straßburger J; Baqi Y; Müller CE; von Kügelgen I
J Thromb Haemost; 2014 Nov; 12(11):1898-905. PubMed ID: 25186974
[TBL] [Abstract][Full Text] [Related]
2. Interaction of new, very potent non-nucleotide antagonists with Arg256 of the human platelet P2Y12 receptor.
Hoffmann K; Baqi Y; Morena MS; Glänzel M; Müller CE; von Kügelgen I
J Pharmacol Exp Ther; 2009 Nov; 331(2):648-55. PubMed ID: 19690189
[TBL] [Abstract][Full Text] [Related]
3. SAR216471, an alternative to the use of currently available P2Y₁₂ receptor inhibitors?
Delesque-Touchard N; Pflieger AM; Bonnet-Lignon S; Millet L; Salel V; Boldron C; Lassalle G; Herbert JM; Savi P; Bono F
Thromb Res; 2014 Sep; 134(3):693-703. PubMed ID: 25064036
[TBL] [Abstract][Full Text] [Related]
4. P2Y12 antagonist ticagrelor inhibits the release of procoagulant extracellular vesicles from activated platelets.
Gasecka A; Nieuwland R; van der Pol E; Hajji N; Ćwiek A; Pluta K; Konwerski M; Filipiak KJ
Cardiol J; 2019; 26(6):782-789. PubMed ID: 29671861
[TBL] [Abstract][Full Text] [Related]
5. Inverse agonism at the P2Y12 receptor and ENT1 transporter blockade contribute to platelet inhibition by ticagrelor.
Aungraheeta R; Conibear A; Butler M; Kelly E; Nylander S; Mumford A; Mundell SJ
Blood; 2016 Dec; 128(23):2717-2728. PubMed ID: 27694321
[TBL] [Abstract][Full Text] [Related]
6. Ticagrelor binds to human P2Y(12) independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation.
VAN Giezen JJ; Nilsson L; Berntsson P; Wissing BM; Giordanetto F; Tomlinson W; Greasley PJ
J Thromb Haemost; 2009 Sep; 7(9):1556-65. PubMed ID: 19552634
[TBL] [Abstract][Full Text] [Related]
7. Involvement of basic amino acid residues in transmembrane regions 6 and 7 in agonist and antagonist recognition of the human platelet P2Y(12)-receptor.
Hoffmann K; Sixel U; Di Pasquale F; von Kügelgen I
Biochem Pharmacol; 2008 Nov; 76(10):1201-13. PubMed ID: 18809389
[TBL] [Abstract][Full Text] [Related]
8. Farnesyl pyrophosphate is an endogenous antagonist to ADP-stimulated P2Y₁₂ receptor-mediated platelet aggregation.
Högberg C; Gidlöf O; Deflorian F; Jacobson KA; Abdelrahman A; Müller CE; Olde B; Erlinge D
Thromb Haemost; 2012 Jul; 108(1):119-32. PubMed ID: 22628078
[TBL] [Abstract][Full Text] [Related]
9. Influence of P2Y12 polymorphisms on platelet activity but not ex-vivo antiplatelet effect of ticagrelor in healthy Chinese male subjects.
Li MP; Tang J; Wen ZP; Zhang YJ; Zhang W; Zhou HH; Zhang ZL; Chen XP
Blood Coagul Fibrinolysis; 2015 Dec; 26(8):874-81. PubMed ID: 26083990
[TBL] [Abstract][Full Text] [Related]
10. Ticagrelor inverse agonist activity at the P2Y
Khalil J; Dimofte T; Roberts T; Keith M; Amaradasa K; Hindle MS; Bancroft S; Hutchinson JL; Naseem K; Johnson T; Mundell SJ
Br J Pharmacol; 2024 Jan; 181(1):21-35. PubMed ID: 37530222
[TBL] [Abstract][Full Text] [Related]
11. Adenosine derived from ADP can contribute to inhibition of platelet aggregation in the presence of a P2Y12 antagonist.
Iyú D; Glenn JR; White AE; Fox SC; Heptinstall S
Arterioscler Thromb Vasc Biol; 2011 Feb; 31(2):416-22. PubMed ID: 21106949
[TBL] [Abstract][Full Text] [Related]
12. Effect of ticagrelor on endothelial calcium signalling and barrier function.
Gündüz D; Tanislav C; Schlüter KD; Schulz R; Hamm C; Aslam M
Thromb Haemost; 2017 Jan; 117(2):371-381. PubMed ID: 27904901
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and biological evaluation of ticagrelor derivatives as novel antiplatelet agents.
Zhang H; Liu J; Zhang L; Kong L; Yao H; Sun H
Bioorg Med Chem Lett; 2012 Jun; 22(11):3598-602. PubMed ID: 22546677
[TBL] [Abstract][Full Text] [Related]
14. Regulation of functionally active P2Y12 ADP receptors by thrombin in human smooth muscle cells and the presence of P2Y12 in carotid artery lesions.
Rauch BH; Rosenkranz AC; Ermler S; Böhm A; Driessen J; Fischer JW; Sugidachi A; Jakubowski JA; Schrör K
Arterioscler Thromb Vasc Biol; 2010 Dec; 30(12):2434-42. PubMed ID: 21071695
[TBL] [Abstract][Full Text] [Related]
15. A clopidogrel-insensitive inducible pool of P2Y12 receptors contributes to thrombus formation: inhibition by elinogrel, a direct-acting, reversible P2Y12 antagonist.
Haberstock-Debic H; Andre P; Mills S; Phillips DR; Conley PB
J Pharmacol Exp Ther; 2011 Oct; 339(1):54-61. PubMed ID: 21730013
[TBL] [Abstract][Full Text] [Related]
16. Characterisation of P2Y(12) receptor responsiveness to cysteinyl leukotrienes.
Foster HR; Fuerst E; Lee TH; Cousins DJ; Woszczek G
PLoS One; 2013; 8(3):e58305. PubMed ID: 23472176
[TBL] [Abstract][Full Text] [Related]
17. Induction of novel agonist selectivity for the ADP-activated P2Y1 receptor versus the ADP-activated P2Y12 and P2Y13 receptors by conformational constraint of an ADP analog.
Chhatriwala M; Ravi RG; Patel RI; Boyer JL; Jacobson KA; Harden TK
J Pharmacol Exp Ther; 2004 Dec; 311(3):1038-43. PubMed ID: 15345752
[TBL] [Abstract][Full Text] [Related]
18. The P2 receptors and congenital platelet function defects.
Cattaneo M
Semin Thromb Hemost; 2005 Apr; 31(2):168-73. PubMed ID: 15852220
[TBL] [Abstract][Full Text] [Related]
19. Incomplete reversibility of platelet inhibition following prolonged exposure to ticagrelor.
Gerrits AJ; Jakubowski JA; Sugidachi A; Michelson AD; Frelinger AL
J Thromb Haemost; 2017 May; 15(5):858-867. PubMed ID: 28092426
[TBL] [Abstract][Full Text] [Related]
20. P2Y12 platelet receptors: importance in percutaneous coronary intervention.
Falcão FJ; Carvalho L; Chan M; Alves CM; Carvalho AC; Caixeta AM
Arq Bras Cardiol; 2013 Sep; 101(3):277-82. PubMed ID: 23917456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
